ANI Pharmaceuticals (ANIP) News Today

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) is moving higher after reporting strong first-quarter 2026 results and raising its full-year outlook.

• Positive Sentiment: ANI Pharmaceuticals beat Wall Street expectations on both earnings and revenue, reporting $2.05 EPS versus $1.28 expected and revenue of $237.46 million versus $207.63 million expected. The company also said quarterly revenue rose 20.5% year over year, signaling solid underlying growth. Article Title
• Positive Sentiment: The company raised its FY 2026 EPS guidance to $9.19-$9.69, above the consensus estimate of $8.79, which suggests management sees stronger profitability ahead. Article Title
• Neutral Sentiment: Investors are also parsing the earnings call transcript and presentation for details on the company’s growth drivers and updated strategy, but the main stock catalyst today is the beat-and-raise quarter. Article Title
• Neutral Sentiment: ANI also issued revenue guidance around $1.1 billion for FY 2026, roughly in line with expectations, so the revenue outlook appears stable rather than a fresh upside surprise. Article Title

Overall, ANIP is likely trading up because the company delivered a strong earnings beat, posted robust year-over-year growth, and lifted profit guidance for 2026.